Study Stopped
for few participants recruited
Does Pulse-triggered VNS Autostimulation Increase VNS Efficacy
ERAS
Does Additional ECG-triggered Stimulation Increase the Efficacy of Vagus Nerve Stimulation? An Investigator-initiated Prospective, Multinational, Single Blinded, Randomized Cross-over Trial in Patients With VNS-treatment
1 other identifier
observational
6
1 country
1
Brief Summary
This is a research study to investigate whether the use of an extra function of vagus nerve stimulator (VNS) can give an improved effect against epilepsy. Many epileptic seizures are accompanied by an increase in heart rate. One auxiliary function of a new type of stimulator is continuous measurement of cardiac activity, and when pulse rate increases an extra stimulation is delivered. It has been shown that this can interrupt attacks that are about to develop. In this project the investigators will test how well that works for patients in daily life. The new type of stimulator has similar design and location as the old one. Patients who have already been treated with VNS and who need to switch the stimulator because the battery is starting to run out, are asked whether they want to participate. The study is a randomized and blinded cross-over. The activation of the extra feature is done either in the first or the second treatment phase. Which phase is the phase with activated autostimulation will be decided by random selection and the patient does not know when the auxiliary function is started. The study period is 11 months. Patients are asked to fill in some questionnaires on seizures, quality of life and quality of sleep.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at below P25 for all trials
Started Apr 2018
Longer than P75 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
April 3, 2018
CompletedFirst Submitted
Initial submission to the registry
September 17, 2019
CompletedFirst Posted
Study publicly available on registry
September 19, 2019
CompletedPrimary Completion
Last participant's last visit for primary outcome
April 6, 2022
CompletedStudy Completion
Last participant's last visit for all outcomes
April 6, 2022
CompletedNovember 1, 2023
October 1, 2023
4 years
September 17, 2019
October 31, 2023
Conditions
Outcome Measures
Primary Outcomes (1)
Percentage of subjects with >25 % change in seizure frequency
Percentage of subjects with \>25 % change in seizure frequency
after 11 month
Secondary Outcomes (2)
Change in mean National Hospital Seizure Severity Scale score
after 11 month
Change in mean average seizure duration
after 11 month
Interventions
pulse triggered autostimulation
Eligibility Criteria
Eligible for the study are subjects (males and females) 12 years of age or older who had been using a VNS for at least three years with a positive effect and are getting a device replacement due to low battery capacity or who had a replacement and had not started the additional ECG -triggered stimulation before the study.
You may qualify if:
- Subjects, 12 years of age or older, who have a VNS without ECG-triggered auto stimulation implanted, have a positive effect and have a device replacement with model 106 or model 1000 due to low battery capacity,.
- Subjects, who have 2 or more seizure per month and not more than 28 days between seizures during the baseline.
- Subjects, who are on a stable regiment of antiepileptic drug treatment for at least 3 month prior to enrollment and maintain on this regimen throughout the study.
- VNS parameters have not been changed I the last 3 month prior to enrollment.
- Either the subjects or the legal guardian are able to agree to participate by signing the informed consent form.
You may not qualify if:
- Subjects with rapidly progressive neurodegenerative or rapidly progressing neoplastic disease.
- Subjects or legal guardians who are unable to understand the study procedures.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Oslo University Hospitallead
- Filadelfia Epilepsy Hospitalcollaborator
- Rigshospitalet, Denmarkcollaborator
- Universitaire Ziekenhuizen KU Leuvencollaborator
- Tampere University Hospitalcollaborator
Study Sites (1)
Norwegian epilepsy center
Oslo, 0424, Norway
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Oliver Henning, MD
Oslo University Hospital
Study Design
- Study Type
- observational
- Observational Model
- CASE CROSSOVER
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Principal Investigator
Study Record Dates
First Submitted
September 17, 2019
First Posted
September 19, 2019
Study Start
April 3, 2018
Primary Completion
April 6, 2022
Study Completion
April 6, 2022
Last Updated
November 1, 2023
Record last verified: 2023-10
Data Sharing
- IPD Sharing
- Will not share